The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to identify and exploit targetable vulnerabilities that were manifest in endocrine therapy-resistant disease. Using cellular and mouse models of endocrine therapy-sensitive and endocrine therapy-resistant breast cancer, together with contemporary discovery platforms, we identified a targetable pathway that is composed of the transcription factors FOXA1 and GRHL2, a coregulated target gene, the membrane receptor LYPD3, and the LYPD3 ligand, AGR2. Inhibition of the activity of this pathway using blocking antibodies directed against LYPD3 or AGR2 inhibits the growth of endocrine therapy-resistant tumors in mice, providing the rationale for near-term clinical development of humanized antibodies directed against these proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 3×
“Differential expression analysis was performed using DESeq2 (Love et al., 2014) with tximport.”
InfluentialSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw377 · Cited by 10,799
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231 · cited 1×
“The data were then combined using the COMBAT algorithm implemented in the sva package within R (Leek et al., 2012) with a design matrix to account for known co-variates including data source and platform.”
MethodCarroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., et al. (2005) · Cell · doi:10.1016/j.cell.2005.05.008 · Cited by 1,384
Self-citationFoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983 · cited 1×
“We next probed whether the gained FOXA1 binding events in TAMR were associated with increased enhancer function (Lupien et al., 2008; Sérandour et al., 2011).”
BackgroundSelf-citationMcDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178 · cited 1×
“The majority of breast cancers express estrogen receptor-alpha (ERα), and drugs that target the production of estrogens or which directly interfere with the transcriptional activity of ERα have become frontline interventions in the treatment and prevention of this disease (Brodie, 2002; Fisher et al., 1998, 2001; Pero…”
BackgroundSelf-citation
Cited by
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Pioneering the developmental frontier
Larson, E. D., Marsh, A. J., & Harrison, M. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.020 · Cited by 64
“These estrogen-receptor independent loci are co-occupied by the additional pioneer factor GRHL2, suggesting that two pioneer factors may collaborate to establish novel enhancers, which drive expression of pathways leading to therapy resistance (Cocce et al., 2019).”
BackgroundKumegawa, K., Takahashi, Y., Saeki, S., Yang, L., Nakadai, T., Osako, T., Mori, S., Noda, T., Ohno, S., Ueno, T., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00438-6 · Cited by 45
Metadata
- Authors
- Cocce, K. J., Jasper, J. S., Desautels, T. K., Everett, L., Wardell, S., Westerling, T., Baldi, R., Wright, T. M., Tavares, K., Yllanes, A., Bae, Y., Blitzer, J. T., Logsdon, C., Rakiec, D. P., Ruddy, D. A., Jiang, T., Broadwater, G., Hyslop, T., Hall, A., Laine, M., Phung, L., Greene, G. L., Martin, L.-A., Pancholi, S., Dowsett, M., Detre, S., Marks, J. R., Crawford, G. E., Brown, M., Norris, J. D., Chang, C.-Y., & McDonnell, D. P.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 29
- Issue
- 4
- Pages
- 889-903.e10
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2982007450
- Cited by
- 76
- References
- 8
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. https://app.cochat.ai/papers/10.1016/j.celrep.2019.09.032
- The paper
- Cocce, K. J., Jasper, J. S., Desautels, T. K., Everett, L., Wardell, S., Westerling, T., Baldi, R., Wright, T. M., Tavares, K., Yllanes, A., Bae, Y., Blitzer, J. T., Logsdon, C., Rakiec, D. P., Ruddy, D. A., Jiang, T., Broadwater, G., Hyslop, T., Hall, A., . . . McDonnell, D. P. (2019). The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer. Cell Reports. https://doi.org/10.1016/j.celrep.2019.09.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.